Pharmacological treatment with memantine of oscilloscopy in patients s
Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study.
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Memantine
What it measured
Main measures
the primary outcome measure will be a reduction of > 33% of oscilloscopy as assessed by the VAS and improvement of visual acuity assessed by SVS.
Vision
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion:  male or female aged 18-60 yrs Exclusion:  current treatment with GABAergic drugs from at least 30 days prior to baseline visit
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To investigate the efficacy of memantine on symptomatic oscillopsy by means of the VAS and the Snellen Visual Scale (SVS). The primary end point is the reduction of symptoms (VAS score)
Loading reviews and guidelines…
Related trials
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiot
Phase 3 · Not yet recruiting
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
- Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Me
Phase 3 · Stopped early
Stopped
- Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinica
Phase 3 · Completed
Missed its main goal
- Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Ther
Phase 3 · Stopped early
Stopped
History
Started
Mar 2008